 |
市場調查報告書
商品編碼
2008170
人類胚胎幹細胞市場：依產品和地區分類Human Embryonic Stem Cells Market, By Product (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, and Toxicology Testing) , By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) |
||||||
預計2026年，人類胚胎幹細胞（人類ES細胞）市場規模將達15億美元，2033年將達21億美元。預計從2026年到2033年，其複合年成長率將達到9.72%。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2025 | 市場規模（2026 年） | 15億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2026-2033 |
| 預測期（2026-2033 年）複合年成長率 | 9.72% | 預計金額（2033 年） | 21億美元 |
幹細胞是一種能夠分化成其他類型細胞的生物細胞，可用於治療目的。近年來，隨著技術的進步和技術創新，幹細胞療法開闢了許多潛在的治療方法，使得人類胚胎幹細胞治療方法在全球範圍內廣泛應用。人類胚胎幹細胞正逐漸成為細胞治療領域極具潛力的候選細胞，能夠修復受損細胞和組織的功能。此外，人類胚胎幹細胞（hESCs）具有巨大的治療潛力，有望成為心臟病和惡性腫瘤的標準治療方法。
市場動態
心臟病和惡性腫瘤發病率上升、對幹細胞治療方法的研發日益關注、再生醫學需求不斷成長以及政府和私營機構的支持力度加大，預計這些因素將推動全球人類胚胎幹細胞市場在預測期內成長。
例如，2021 年 4 月，Vertex Pharmaceuticals 獲得了美國食品藥物管理局(FDA) 授予的 VX-880簡審類，並開始對 1 型糖尿病、嚴重低血糖症和低血糖識別能力受損的患者進行 VX-880 的臨床試驗。
2020年2月，全球幹細胞治療與研究中心（GIOSTAR）宣佈在印度開設新的幹細胞、癌症研究與治療中心。該中心的成立標誌著GIOSTAR全球擴張策略的最新里程碑，其主導印度、墨西哥、美國等眾多國家。
本報告的主要特點
- 本報告對全球人類胚胎幹細胞市場進行了詳細分析，包括市場規模和預測期（2026-2033 年）的複合年成長率，以 2025 年為基準年。
- 此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本節根據以下參數，對全球人類胚胎幹細胞市場的主要企業進行介紹：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
- 《全球人類胚胎幹細胞市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球人類胚胎幹細胞市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 市場趨勢
- 主要進展
- 產品核准
- 商業夥伴關係、企業合併
- 監理情勢
- PEST分析
- 波特五力分析
- 流行病學
- 固體管道分析
第4章：全球人類胚胎幹細胞市場：依產品分類（2026-2033 年）
- 再生醫學
- 幹細胞生物學概覽
- 組織工程
- 毒性測試
第5章：全球人類胚胎幹細胞市場：依地區分類（2026-2033年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第6章 競爭情勢
- 熱圖分析
- 市佔率分析
- 公司簡介
- Takara Bio Inc.
- ViaCyte Inc.
- PromoCell GmbH
- Merck KgaA
- PeproTech Inc.
- Astellas Pharma Inc.
- Thermo Fisher Scientific
- Lineage Cell Therapeutics Inc.
- STEMCELL Technologies Inc.
第7章
- 參考
- 分析方法
- 關於 Coherent Market Insights
Human Embryonic Stem Cells Market is estimated to be valued at USD 1.5 Bn in 2026 and is expected to reach USD 2.1 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.72% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.72% | 2033 Value Projection: | USD 2.1 Bn |
Stem cells are biological cells that can differentiate into other types of cells, and are used for therapeutic purposes. Recent developments or advancements have paved the way for a plethora of potential therapies, due to which, therapies involving human embryonic stem cells are being widely adopted worldwide. Human embryonic stem cells have emerged as attractive candidates for cell-based therapies that are capable of restoring lost cell and tissue function. Furthermore, human embryonic stem cells (hESC) have a high potential for use in treatment and may become a standard of care for cardiac and malignant diseases.
Market Dynamics
Rise in incidence of cardiac and malignant diseases, increase in focus on the development of stem cell-based therapies, growing demand for regenerative medicines, and increasing support from government and private organizations are major factors expected to drive growth of the global human embryonic stem cells market during the forecast period.
For instance, in April 2021, Vertex Pharmaceuticals received the United States Food and Drug Administration (FDA) Fast Track Designation for VX-880, and the company initiated a clinical trial for VX-880 in patients who have type 1 diabetes with severe hypoglycemia and impaired hypoglycemic awareness.
In February 2020, Global Institute of Stem Cell Therapy and Research (GIOSTAR) announced the inauguration of a new stem cell / cancer research and therapy center in India. This facility represents the latest milestone in global expansion efforts spearheaded by GIOSTAR in India, Mexico, the United States, and numerous other countries.
Key features of the study
- The report provides in-depth analysis of the global human embryonic stem cells market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global human embryonic stem cells market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA, PeproTech Inc., Astellas Pharma Inc., Thermo Fisher Scientific, Lineage Cell Therapeutics Inc., and STEMCELL Technologies Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global human embryonic stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human embryonic stem cells market.
Market Segmentation
- By Product
- Regenerative Medicine
- Stem Cell Biology Research
- Tissue Engineering
- Toxicology Testing
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Takara Bio Inc.
- ViaCyte Inc.
- PromoCell GmbH
- Merck KgaA
- PeproTech Inc.
- Astellas Pharma Inc.
- Thermo Fisher Scientific
- Lineage Cell Therapeutics Inc.
- STEMCELL Technologies Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Human Embryonic Stell Cells Market, By Product, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
- Regenerative Medicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Stem Cell Biology Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Tissue Engineering
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Toxicology Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
5. Global Human Embryonic Stell Cells Market, By Region, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
6. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Takara Bio Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- ViaCyte Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PromoCell GmbH
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck KgaA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PeproTech Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Lineage Cell Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- STEMCELL Technologies Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
7. Section
- References
- Research Methodology
- About Us
